Drugs / Tirelizumab
Trials 21 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05448781 Background | Jul 2022 → Jul 2023 | non-small cell lung carcinoma | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07062484 Comparator | Jul → Dec 2025 overdue | nasopharyngeal carcinoma | Sichuan Cancer Hospital and Research Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tirelizumab | “Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.” NCT05050630 ↗22“Tirelizumab: a recommended dose of 200mg/ time, administered every three weeks on the first day of each cycle until disease progression or unacceptable toxicity is developed” NCT05448781 ↗ “treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg * q21d” NCT05520814 ↗ “PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen” NCT04860674 ↗ “Toripalimab 240mg or Tirelizumab 200mg or pembrolizumab 200mg intravenously every 3 weeks” NCT06211114 ↗ “PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.” NCT05892237 ↗ “Tirelizumab” NCT05392686 ↗ |
| Action | Inhibit | “PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen” NCT04860674 ↗ |
| Modality | Monoclonal antibody | “PD-1 monoclonal antibody combined with ICE” NCT04860674 ↗ |
| Route | Intravenous | “intravenously infused” NCT04969029 ↗ |